Cutler Group’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-50
Closed -$1K – 2317
2023
Q4
$1K Hold
50
– – ﹤0.01% 3262
2023
Q3
$1K Buy
+50
New +$1.34K ﹤0.01% 3417
2022
Q4
– Sell
-100
Closed -$4.48K – 4390
2022
Q3
$4K Sell
100
-596
-86% -$34K ﹤0.01% 3754
2022
Q2
$26K Sell
696
-229
-25% -$9.1K ﹤0.01% 2450
2022
Q1
$53K Buy
925
+825
+825% +$54.1K ﹤0.01% 2198
2021
Q4
$7K Buy
+100
New +$8.56K ﹤0.01% 3933
2021
Q1
– Sell
-2,500
Closed -$238K – 5621
2020
Q4
$204K Buy
+2,500
New +$123K 0.01% 1071

Other funds holding BEAM

Cutler Group's BEAM Position: Q1 2024 in Review

Cutler Group sold out of Beam Therapeutics (BEAM) in Q1 2024, closing a stake of 50 shares — an estimated $1K sold.

Cutler Group first reported a position in BEAM in Q4 2020 and held it in 7 quarters. The position peaked at $204K in Q4 2020. 221 funds tracked by Wall St. Rank hold BEAM as of Q1 2024.

  • Cutler Group reported no remaining Beam Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 50 Beam Therapeutics shares in Q1 2024, an estimated $1K.
  • Cutler Group first reported a position in Beam Therapeutics in Q4 2020 and held it in 7 quarters.
  • Cutler Group's Beam Therapeutics position peaked at $204K in Q4 2020.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.